BCL7B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal pool of A-549 human lung adenocarcinoma epithelial cells with targeted disruption of the BCL7B gene. This product provides a heterogeneous knockout population, enabling functional studies without clonal artifacts. The gene editing is generated via CRISPR/Cas9-mediated gene disruption, producing a diverse loss-of-function model suitable for initial pathway analysis and screening. The cells are offered as a ready-to-use tool for investigating BCL7B’s tumor-suppressive roles.
The parental A-549 cell line was derived from the lung adenocarcinoma of a 58-year-old male and is a widely adopted model in cancer biology and respiratory research. These adherent epithelial cells display properties of type II alveolar epithelium and harbor oncogenic KRAS mutations, making them relevant for studying non-small cell lung cancer (NSCLC) pathogenesis, drug responses, and signaling networks. A-549 cells are a standard platform for lung adenocarcinoma research.
BCL7B is a putative tumor suppressor implicated in Wnt/??-catenin signaling, apoptosis, and chromatin remodeling. It functions downstream of WNT3A and interacts with ??-catenin and TCF/LEF transcription factors to modulate gene transcription. BCL7B also associates with SWI/SNF chromatin remodeling components and histone deacetylases, suggesting a role in epigenetic regulation. In apoptosis, BCL7B influences the expression of downstream targets such as BAX, BCL2, c-MYC, and CCND1, and may be regulated by p53. Loss of BCL7B is predicted to enhance Wnt-driven proliferation and diminish apoptotic capacity, thereby promoting oncogenic phenotypes.
In A-549 cells, BCL7B knockout is expected to accentuate transformed features by unleashing Wnt/??-catenin signaling and reducing apoptosis. The loss of BCL7B-mediated transcriptional repression may elevate pro-survival BCL2 family members and downregulate pro-apoptotic effectors, while also altering chromatin structure via SWI/SNF interactions. This model thus enables dissection of BCL7B’s tumor-suppressive mechanisms in a lung adenocarcinoma background, offering insights into its functional crosstalk with oncogenic KRAS pathways.
Applications include western blotting and RT-qPCR for expression profiling, MTT and BrdU proliferation assays, and Annexin V/caspase apoptosis studies. Migration and invasion assays can assess metastatic behavior, while ChIP-qPCR and co-immunoprecipitation probe BCL7B interactions. Transcriptomic analysis via RNA-seq reveals downstream targets. This polyclonal knockout cell population supports tumor suppressor research, Wnt pathway interrogation, and drug target validation in lung adenocarcinoma. For additional information, contact Ascent Research.
